AstraZeneca PLC (AZN)
| Market Cap | 286.90B +9.4% |
| Revenue (ttm) | 62.38B +7.3% |
| Net Income | 11.03B +17.4% |
| EPS | 7.10 +17.3% |
| Shares Out | 1.55B |
| PE Ratio | 26.30 |
| Forward PE | 16.60 |
| Dividend | $3.23 (1.73%) |
| Ex-Dividend Date | Aug 7, 2026 |
| Volume | 1,803,199 |
| Open | 186.71 |
| Previous Close | 189.39 |
| Day's Range | 184.96 - 188.10 |
| 52-Week Range | 153.41 - 212.71 |
| Beta | 0.16 |
| Analysts | Buy |
| Price Target | 208.08 (+11.42%) |
| Earnings Date | Oct 30, 2026 |
About AZN
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is $208.08, which is an increase of 11.42% from the latest price.
News
AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced $1.6 million in grants to nonprofit organizations across the US through its Accelerate Change Together (ACT) on Health Equity initiative....
AstraZeneca Gains Single-Cell Bioconjugation Technology Through Omniose Deal
(RTTNews) - AstraZeneca PLC (AZN) has acquired Omniose, a preclinical biotechnology company developing vaccines against serious bacterial infections.
AstraZeneca Acquires Omniose Following Three-Year Research Collaboration
(RTTNews) - AstraZeneca(AZN), has acquired Omniose, a St. Louis-based preclinical biotechnology company, making it a wholly owned subsidiary within its Infectious Disease Unit.
AstraZeneca bolsters vaccine pipeline with US-biotech Omniose acquisition
AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious bacterial infections, and folded the business into its infectious diseases division, the target ...
Omniose Announces Its Acquisition by AstraZeneca
ST. LOUIS--(BUSINESS WIRE)--Omniose, a preclinical biotechnology company, today announced that it has been acquired by AstraZeneca. The acquisition follows a productive three-year exclusive research c...
What Zimmer Biomet (ZBH) Said on Its Q3 Earnings Call
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHZimmer Biomet (NYSE:ZBH) raised its 2026 sales growth and adjusted earnings outlook after third-quarter growth in hips, surgical specialt...
Edwards Lifesciences Q3 Earnings Call Highlights
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences (NYSE:EW) raised its 2026 sales and earnings guidance after third-quarter results exceeded management’s expectations...
US measles status to go up for review
Presented by AstraZeneca {beacon} Healthcare Healthcare The Big Story US measles status to go up for review The U.S. and Mexico will meet with the Pan American Health Organization (PAHO) for a three-d...
Democrats get their health agenda ready ahead of takeover
Presented by AstraZeneca {beacon} Healthcare Healthcare The Big Story Democrats get their health agenda ready ahead of takeover Reinstating the Affordable Care Act’s enhanced premium tax credits, reve...
AstraZeneca recently made $10B offer to buy Rhythm Pharmaceuticals, WSJ says
AstraZeneca (AZN) recently made a roughly $10B offer to acquire Rhythm Pharmaceuticals (RYTM) for $124 per share, according to people familiar with the matter, The Wall Street Journal’s Lauren Thomas…
AstraZeneca Made $10 Billion Offer for Rhythm Pharmaceuticals
Rhythm specializes in treatments for metabolic conditions and severe obesity.
AstraZeneca Breaks Above 200-Day Moving Average - Bullish for AZN
In trading on Wednesday, shares of AstraZeneca plc (Symbol: AZN) crossed above their 200 day moving average of $188.20, changing hands as high as $189.66 per share. AstraZeneca plc shares are currentl...
Pfizer (PFE) vs. AstraZeneca (AZN): Which Pharma Stock Offers a Better Dividend?
Pfizer ($PFE) and AstraZeneca ($AZN) are two U.S. pharmaceutical companies that offer dividends. Both offer dividend yields above the broader market, but Pfizer offers quarterly dividends, while Astra...
Edwards Lifesciences Highlights PASCAL, TAVR Data Showing Patient Benefits
A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHEdwards Lifesciences (NYSE:EW) highlighted new clinical data for its transcatheter tricuspid repair and transcatheter aortic valve replac...
AstraZeneca price target raised to 18,900 GBp from 18,600 GBp at Citi
Citi analyst Graham Parry raised the firm’s price target on AstraZeneca (AZN) to 18,900 GBp from 18,600 GBp and keeps a Buy rating on the shares.
AstraZeneca price target raised to 17,000 GBp from 16,000 GBp at Barclays
Barclays raised the firm’s price target on AstraZeneca (AZN) to 17,000 GBp from 16,000 GBp and keeps an Overweight rating on the shares.
AstraZeneca price target raised to 15,250 GBp from 14,500 GBp at RBC Capital
RBC Capital raised the firm’s price target on AstraZeneca (AZN) to 15,250 GBp from 14,500 GBp and keeps an Outperform rating on the shares. The company’s solid Q3 performance underscores…
AstraZeneca: 3 Key Takeaways for Long-Term Investors
Strategic partnerships and accelerating trial readouts position the company to replace revenue lost to patent cliffs.
AstraZeneca chief Pascal Soriot eyes record £28m pay package bonanza
Pascal Soriot is already the highest-paid FTSE 100 chief executive, landing £17.7m last year at the Anglo-Swedish drugs giant.
AstraZeneca (AZN) Q3 2026 Earnings Call Transcript
Oncology and rare disease momentum offset cardiovascular headwinds.
AstraZeneca Q3 Earnings Call Highlights
AstraZeneca NYSE: AZN reported continued revenue and earnings growth for the first nine months of 2026, supported by double-digit expansion in oncology, rare disease and respiratory and immunology, wh...
AstraZeneca Q3 Earnings Call Highlights
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite DirectionsAstraZeneca (NYSE:AZN) reported continued revenue and earnings growth for the first nine months of 2026, supported by dou...
Friday's ETF Movers: PPH, PSI
In trading on Friday, the VanEck Pharmaceutical ETF is outperforming other ETFs, up about 2.4% on the day. Components of that ETF showing particular strength include shares of Astrazeneca, up about 7....
AstraZeneca Gaps Up To Three-Month High As CEO Calls Out $20 Billion Potential
AstraZeneca stock gapped higher Friday as cancer drugs Enhertu and Tagrisso lent themselves to a solid third-quarter report.
AstraZeneca Earnings Call Transcript: Q3 2026
9M revenue grew 7% and core EPS 14%, led by oncology, rare disease, and R&I. A deep pipeline, including more than 20 planned 2027 Phase III readouts, supports the $80B 2030 ambition.